Olsson RF, Logan BR, Chaudhury S, Zhu X, Akpek G, Bolwell BJ, et al. Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies. Leukemia. 2015;29:1754–62.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kharfan-Dabaja MA, Kumar A, Ayala E, Aljurf M, Nishihori T, Marsh R, et al. Standardizing definitions of hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the american society for transplantation and cellular therapy. Transpl Cell Ther. 2021;27:642–9.

Article  CAS  Google Scholar 

Merli P, Caruana I, De Vito R, Strocchio L, Weber G, Bufalo FD, et al. Role of interferon-gamma in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation. Haematologica. 2019;104:2314–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sabulski A, Myers KC, Bleesing JJ, Duell A, Lane A, Teusink-Cross A, et al. Graft rejection markers in children undergoing hematopoietic cell transplant for bone marrow failure. Blood Adv. 2021;5:4594–604.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rottman M, Soudais C, Vogt G, Renia L, Emile JF, Decaluwe H, et al. IFN-gamma mediates the rejection of haematopoietic stem cells in IFN-gammaR1-deficient hosts. PLoS Med. 2008;5:e26.

Article  PubMed  PubMed Central  Google Scholar 

Sabulski A, Langenberg L, Luebbering N, Libermann T, Dillon S, Koo J, et al. Plasma proteome analyses identify predictors of graft rejection prior to stem cell infusion and support interferon-mediated ferroptosis as a novel mechanism of graft rejection. Transpl Cell Ther. 2024;30:S4–5.

Jacqmin P, Laveille C, Snoeck E, Jordan MB, Locatelli F, Ballabio M, et al. Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: a pharmacometric model-based approach. Br J Clin Pharm. 2022;88:2128–39.

Article  CAS  Google Scholar 

Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N. Engl J Med. 2020;382:1811–22.

Article  PubMed  Google Scholar 

Ottaviano G, Chiesa R, Feuchtinger T, Vickers MA, Dickinson A, Gennery AR, et al. Adoptive T cell therapy strategies for viral infections in patients receiving haematopoietic stem cell transplantation. Cells. 2019;8:47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gardner JC, Courter JD, Dandoy CE, Davies SM, Teusink-Cross A. Safety and efficacy of prophylactic levofloxacin in pediatric and adult hematopoietic stem cell transplantation patients. Transpl Cell Ther. 2022;28:167.e1–167.e5.

Article  CAS  Google Scholar 

Weber G, Strocchio L, Del Bufalo F, Algeri M, Pagliara D, Arnone CM, et al. Identification of new soluble factors correlated with the development of graft failure after haploidentical hematopoietic stem cell transplantation. Front Immunol. 2020;11:613644.

Article  CAS  PubMed  Google Scholar 

Tucci F, Gallo V, Barzaghi F, Ferrua F, Migliavacca M, Calbi V, et al. Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis-related graft failure and disseminated bacillus Calmette-Guérin infection. Haematologica. 2021;106:641–6.

Article  PubMed  Google Scholar 

Kunvarjee B, Bidgoli A, Madan RP, Vidal E, McAvoy D, Hosszu KK, et al. Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations. J Allergy Clin Immunol. 2023;152:815–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Svahn BM, Remberger M, Alvin O, Karlsson H, Ringdén O. Increased costs after allogeneic haematopoietic SCT are associated with major complications and re-transplantation. Bone Marrow Transpl. 2012;47:706–15.

Article  Google Scholar